pubrio
ALTEOGEN Inc. logo

ALTEOGEN Inc.

Public
alteogen.com
जैव प्रौद्योगिकी29 employeesFounded 2008🇰🇷 दक्षिण कोरिया

Alteogen is a leading biopharmaceutical company with a robust pipeline of next-generation biologics featuring enhanced efficacy, enabled by its proprietary platform technologies. Founded in 2008, the company is listed on the KOSDAQ stock exchange (KRX:196170). Alteogen’s most distinguished platform, Hybrozyme™, is a novel human hyaluronidase technology that enhances the absorption of biologic drugs administered via subcutaneous injection. This proprietary hyaluronidase demonstrates improved enzymatic activity and thermal stability compared to existing alternatives. Another key innovation, NexP™ fusion technology, is designed to extend the half-life of therapeutic proteins and peptides in the human body. It is currently applied to the development of long-acting biologics, including human growth hormone, exenatide (for diabetes), and Factor VIIa (for hemophilia). The company’s proprietary antibody-drug conjugate platform, NexMab™ ADC technology, enables targeted cancer therapies with improved efficacy and reduced side effects. Using this platform, Alteogen is developing ADC therapeutics for breast, gastric, and ovarian cancers. With extensive expertise and experience, Alteogen has also established its own high-expression cell lines, efficient upstream and downstream processes, and optimized analytical methods to support the development of monoclonal antibody biosimilars.

स्थापना वर्ष
2008
कर्मचारी
29
उद्योग
जैव प्रौद्योगिकी
कंपनी का प्रकार
Public Company
स्टॉक
koe: 196170.KQ
मुख्यालय
🇰🇷Yuseong-gu, Daejeon (+3)
विशेषज्ञताएँ
फार्मास्यूटिकल्सजैव प्रौद्योगिकीचिकित्सा

विस्तार इंटेलिजेंस

नया · केवल Pubrio पर

हम ALTEOGEN Inc. के बाज़ार विस्तार को ट्रैक कर रहे हैं

वैश्विक विस्तार

लाइव
चरण
खोज मेंनिवेश मेंप्रवेश मेंसंचालन में

गतिविधि पल्स

पिछले 90 दिनों में 2 सिग्नल।

पिछले 90 दिन
भर्ती
0
कोई गतिविधि नहीं
मार्केटिंग और PR
2समाप्त
समाचार / PR
प्रोडक्ट और टेक
0
कोई गतिविधि नहीं
+2और श्रेणियाँलॉक्ड
5 में से 3 दिख रहे
जानना अच्छा है

ALTEOGEN Inc. से जुड़े सामान्य प्रश्न

ALTEOGEN Inc. के व्यवसाय, बाज़ारों और ग्रोथ सिग्नल के बारे में त्वरित उत्तर।

Alteogen is a leading biopharmaceutical company with a robust pipeline of next-generation biologics featuring enhanced efficacy, enabled by its proprietary platform technologies. Founded in 2008, the company is listed on the KOSDAQ stock exchange (KRX:196170). Alteogen’s most distinguished platform, Hybrozyme™, is a novel human hyaluronidase technology that enhances the absorption of biologic drugs administered via subcutaneous injection. This proprietary hyaluronidase demonstrates improved enzymatic activity and thermal stability compared to existing alternatives. Another key innovation, NexP™ fusion technology, is designed to extend the half-life of therapeutic proteins and peptides in the human body. It is currently applied to the development of long-acting biologics, including human growth hormone, exenatide (for diabetes), and Factor VIIa (for hemophilia). The company’s proprietary antibody-drug conjugate platform, NexMab™ ADC technology, enables targeted cancer therapies with improved efficacy and reduced side effects. Using this platform, Alteogen is developing ADC therapeutics for breast, gastric, and ovarian cancers. With extensive expertise and experience, Alteogen has also established its own high-expression cell lines, efficient upstream and downstream processes, and optimized analytical methods to support the development of monoclonal antibody biosimilars.

आज ही अपनी यात्रा शुरू करें

चाहे प्लेटफ़ॉर्म से शुरू करें या बातचीत से

आप खुद Pubrio का उपयोग कर सकते हैं या हमारी टीम से रिसर्च, लीड जेनरेशन या डेटा इंटीग्रेशन में मदद ले सकते हैं।

हमारी टीम से बात करें
Start Journey Image
pubrio

Pubrio 50+ लोकल स्रोतों से बिज़नेस, लोगों और इंटेंट डेटा को एक वैश्विक ग्राफ़ में जोड़ता है, जिससे AI और रेवेन्यू टीमों को पूरा बाज़ार दिखाई देता है।

© 2026 Pubrio. सर्वाधिकार सुरक्षित।